Paper42852014PubMed
Reassessing Viral Gene Therapy for Glioblastoma: Translational Opportunities and Challenges.
Madani J and 2 others. Yale J Biol Med, 2026.
Cite this record
ConductScience Library. Reassessing Viral Gene Therapy for Glioblastoma: Translational Opportunities and Challenges. Papers, record 42852014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42852014
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Reassessing Viral Gene Therapy for Glioblastoma: Translational Opportunities and Challenges.
- Journal
- Yale J Biol Med
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-13
Source PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Brain Neoplasms | Major topic |
| Genetic Therapy | Major topic |
| Glioblastoma | Major topic |
| Translational Research, Biomedical | Major topic |
| Animals | |
| Humans | |
| CRISPR-Cas Systems | |
| Gene Therapy Agents | |
| Oncolytic Virotherapy | |
| Oncolytic Viruses |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36428586 | Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36428586 | PubMed |
| 2 | 38267500 | Identification of genes with oscillatory expression in glioblastoma: the paradigm of SOX2. | Sci Rep | 2024 | https://conductscience.org/library/papers/38267500 | PubMed |
| 3 | 24294541 | Suicide Gene Therapy for Cancer - Current Strategies. | J Genet Syndr Gene Ther | 2013 | https://conductscience.org/library/papers/24294541 | PubMed |
| 4 | 40745004 | Applications of multiplexed CRISPR-Cas for genome engineering. | Exp Mol Med | 2025 | https://conductscience.org/library/papers/40745004 | PubMed |
| 5 | 36970624 | Off-target effects in CRISPR/Cas9 gene editing. | Front Bioeng Biotechnol | 2023 | https://conductscience.org/library/papers/36970624 | PubMed |
| 6 | 41063230 | New experimental therapies for glioblastoma: a review of preclinical research. | Acta Neuropathol Commun | 2025 | https://conductscience.org/library/papers/41063230 | PubMed |
| 7 | 29668458 | On the Concepts and History of Glioblastoma Multiforme - Morphology, Genetics and Epigenetics. | Folia Med (Plovdiv) | 2018 | https://conductscience.org/library/papers/29668458 | PubMed |
| 8 | 38275409 | CRISPR/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review. | Biomedicines | 2024 | https://conductscience.org/library/papers/38275409 | PubMed |
| 9 | 26072401 | Evaluation of Bystander Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis. | Methods Mol Biol | 2015 | https://conductscience.org/library/papers/26072401 | PubMed |
| 10 | 37245011 | Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial. | J Transl Med | 2023 | https://conductscience.org/library/papers/37245011 | PubMed |
| 11 | 35689624 | Epigenetic features drastically impact CRISPR-Cas9 efficacy in plants. | Plant Physiol | 2022 | https://conductscience.org/library/papers/35689624 | PubMed |
| 12 | 30627060 | Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. | Contrast Media Mol Imaging | 2018 | https://conductscience.org/library/papers/30627060 | PubMed |
| 13 | 36823172 | Spatial transcriptomics reveals niche-specific enrichment and vulnerabilities of radial glial stem-like cells in malignant gliomas. | Nat Commun | 2023 | https://conductscience.org/library/papers/36823172 | PubMed |
| 14 | 39752252 | Single-nucleus and spatial landscape of the sub-ventricular zone in human glioblastoma. | Cell Rep | 2025 | https://conductscience.org/library/papers/39752252 | PubMed |
| 15 | 11353831 | Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. | Proc Natl Acad Sci U S A | 2001 | https://conductscience.org/library/papers/11353831 | PubMed |
| 16 | 35864254 | Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. | Nat Med | 2022 | https://conductscience.org/library/papers/35864254 | PubMed |
| 17 | 19098898 | Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. | Nat Biotechnol | 2009 | https://conductscience.org/library/papers/19098898 | PubMed |
| 18 | 38720342 | Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. | J Hematol Oncol | 2024 | https://conductscience.org/library/papers/38720342 | PubMed |
| 19 | 28798809 | Hypoxia-inducible tumour-specific promoters as a dual-targeting transcriptional regulation system for cancer gene therapy. | Ecancermedicalscience | 2017 | https://conductscience.org/library/papers/28798809 | PubMed |
| 20 | 31750274 | Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma. | Oncolytic Virother | 2019 | https://conductscience.org/library/papers/31750274 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42852014
GET https://conductscience.org/api/papers/v1/42852014/references?page=2